 |
市場調查報告書
商品編碼
1898323
中樞神經系統生物標記市場規模、佔有率和成長分析（按類型、應用、最終用戶和地區分類）—產業預測，2026-2033年Central Nervous System Biomarkers Market Size, Share, and Growth Analysis, By Type (Safety Biomarkers, Efficacy Biomarkers), By Application (Diagnostics, Drug Discovery & Development), By End-User, By Region - Industry Forecast 2026-2033 |
||||||
全球中樞神經系統生物標記市場規模預計在 2024 年達到 60.5 億美元，從 2025 年的 65.4 億美元成長到 2033 年的 122 億美元，在預測期（2026-2033 年）內複合年成長率為 8.1%。
受人口結構和生活方式變化的影響，神經系統疾病發病率不斷上升，推動了全球中樞神經系統生物標記市場顯著成長。這種盛行率的激增促使人們對精準早期診斷的需求日益成長，並促進了基於生物標記的診斷技術的應用。研發領域的創新不斷加深我們對中樞神經系統疾病分子和遺傳基礎的理解，催生了靈敏度和特異性更高的新型生物標記。此外，個人化醫療的興起使得生物標記分析對於最佳化患者選擇和治療監測至關重要。儘管面臨標準化需求、監管障礙以及中樞神經系統疾病固有的複雜性等挑戰，中樞神經系統生物標記在推進神經科學領域的治療策略和藥物研發方面仍然發揮關鍵作用。
全球中樞神經系統生物標記市場促進因素
包括阿茲海默症、帕金森氏症和多發性硬化症在內的神經系統疾病發病率不斷上升，顯著推動了中樞神經系統（CNS）生物標記市場的成長。隨著這些疾病的日益普遍，對準確及時診斷的需求也日益迫切，促使醫療服務提供者和研究人員尋求基於生物標記的創新診斷解決方案。對神經系統疾病早期檢測和有效管理的日益重視，推動了對先進生物標記的需求，最終重塑了中樞神經系統診斷市場的模式。此外，對改善患者預後的追求也進一步增強了對這些關鍵診斷工具的依賴。
限制全球中樞神經系統生物標記市場的因素
由於中樞神經系統疾病的複雜性和多面性，全球中樞神經系統生物標記市場面臨嚴峻挑戰。這種複雜性使得識別能夠真正反映疾病潛在機制的可靠且特異性的生物標記變得困難。此外，不同中樞神經系統疾病之間的差異也使得通用生物標記的開發更加複雜，因為它們可能無法與這些疾病的各種臨床表現和病理過程完全對應。因此，尋找能夠有效指導診斷和治療的精準生物標記仍然是該市場的主要障礙，阻礙了發展和創新。
全球中樞神經系統生物標記市場趨勢
全球中樞神經系統生物標記市場正經歷一場變革性的演變，而這主要得益於技術的顯著進步。高通量篩檢技術、次世代定序和先進的成像方式等創新技術正在提高生物標記檢測的靈敏度和特異性。這些進步不僅提高了中樞神經系統疾病診斷和監測的準確性，也促進了個人化醫療的實現。由此產生的對可靠、精準生物標記的需求，刺激了生物技術公司、研究機構和醫療服務提供者之間的投資與合作，從而推動了這個充滿活力的市場的成長。
目錄
介紹
- 調查目標
- 調查範圍
- 定義
調查方法
- 資訊收集
- 二手資料和一手資料方法
- 市場規模預測
- 市場假設與限制
執行摘要
- 全球市場展望
- 供需趨勢分析
- 細分市場機會分析
市場動態與展望
- 市場規模
- 市場動態
- 促進因素和機遇
- 限制與挑戰
- 波特分析
關鍵市場考察
- 關鍵成功因素
- 競爭程度
- 關鍵投資機會
- 市場生態系統
- 市場吸引力指數（2025）
- PESTEL 分析
- 總體經濟指標
- 價值鏈分析
- 定價分析
- 案例研究
- 監管環境
- 專利分析
全球中樞神經系統生物標記市場規模（按類型和複合年成長率分類）（2026-2033 年）
- 安全生物標記
- 療效生物標記
- 檢驗的生物標記
全球中樞神經系統生物標記市場規模（按應用及複合年成長率分類）（2026-2033 年）
- 診斷
- 阿茲海默症
- 帕金森氏症
- 多發性硬化症
- 中風
- 藥物發現與開發
- 臨床前試驗
- 臨床試驗
- 個人化醫療
- 基因生物標記
- 蛋白質體學生物標記
- 代謝體學物標誌物
全球中樞神經系統生物標記市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）
- 醫院
- 診斷檢查室
- 研究所
- 生物製藥公司
全球中樞神經系統生物標記市場規模及複合年成長率（2026-2033）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
- 拉丁美洲
- 巴西
- 其他拉丁美洲
- 中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區
競爭資訊
- 前五大公司對比
- 主要企業的市場定位（2025 年）
- 主要市場參與者所採取的策略
- 近期市場趨勢
- 公司市佔率分析（2025 年）
- 主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較
主要企業簡介
- F. Hoffmann-La Roche Ltd（Switzerland）
- Novartis AG（Switzerland）
- Siemens Healthineers AG（Germany）
- Thermo Fisher Scientific Inc.（USA）
- Abbott Laboratories（USA）
- Merck KGaA（Germany）
- Eurofins Scientific（Luxembourg）
- Charles River Laboratories International, Inc.（USA）
- PerkinElmer Inc.（USA）
- Bio-Rad Laboratories, Inc.（USA）
- QIAGEN NV（Netherlands）
- Axon Neuroscience SE（Slovakia）
- Alector Inc.（USA）
- Oryzon Genomics SA（Spain）
- Banyan Biomarkers Inc.（USA）
- Avacta Group PLC（UK）
- Geno Technology Inc.（USA）
- Anavex Life Sciences Corp.（USA）
- Alseres Pharmaceuticals Inc.（USA）
- Aposense Ltd.（Israel）
結論與建議
Global Central Nervous System Biomarkers Market size was valued at USD 6.05 Billion in 2024 and is poised to grow from USD 6.54 Billion in 2025 to USD 12.2 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).
The global market for CNS biomarkers is witnessing substantial growth, fueled by the rising incidence of neurological disorders, influenced by demographic shifts and lifestyle changes. This surge in prevalence prompts a heightened demand for precision in early diagnosis, fostering the use of biomarker-based diagnostic technologies. Innovations in research are enhancing our comprehension of the molecular and genetic underpinnings of CNS conditions, leading to the emergence of novel biomarkers that improve sensitivity and specificity. Furthermore, the shift towards personalized medicine necessitates biomarker analysis for optimized patient selection and treatment monitoring. Despite challenges such as the need for standardization, regulatory hurdles, and the intrinsic complexity of CNS disorders, CNS biomarkers remain pivotal in advancing therapeutic strategies and drug development in neuroscience.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Central Nervous System Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Central Nervous System Biomarkers Market Segments Analysis
Global Central Nervous System Biomarkers Market is segmented by Type, Application, End-User and region. Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers. Based on Application, the market is segmented into Diagnostics, Drug Discovery & Development and Personalized Medicine. Based on End-User, the market is segmented into Hospitals, Diagnostic Laboratories, Research Institutes and Biopharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Central Nervous System Biomarkers Market
The increasing incidence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, significantly propels the growth of the Central Nervous System (CNS) biomarkers market. As these conditions become more widespread, the urgent need for precise and timely diagnoses intensifies, driving healthcare providers and researchers to seek innovative biomarker-based diagnostic solutions. This heightened focus on early detection and effective management of neurological diseases fosters a growing demand for advanced biomarkers, ultimately shaping the landscape of the CNS diagnostics market. Moreover, the quest for improved patient outcomes further amplifies the reliance on these critical diagnostic tools.
Restraints in the Global Central Nervous System Biomarkers Market
The Global Central Nervous System Biomarkers market faces significant challenges due to the intricate and multifaceted nature of CNS disorders. This complexity makes it difficult to pinpoint reliable and specific biomarkers that truly represent the underlying disease mechanisms. Furthermore, the variability among different CNS conditions complicates the development of universal biomarkers, as they may not uniformly correlate with the diverse clinical manifestations and pathological processes of these disorders. As a result, the quest for accurate biomarkers that can effectively guide diagnosis and treatment remains a significant obstacle within this market, hindering progress and innovation.
Market Trends of the Global Central Nervous System Biomarkers Market
The Global Central Nervous System Biomarkers market is experiencing a transformative evolution driven by significant technological advancements. Innovations like high-throughput screening techniques, next-generation sequencing, and sophisticated imaging modalities are enhancing the sensitivity and specificity of biomarker detection. This surge in technology not only improves the accuracy of diagnosing and monitoring central nervous system disorders but also facilitates personalized medicine approaches. As a result, the demand for reliable and precise biomarkers is rising, attracting investment and fostering collaborations among biotech firms, research institutions, and healthcare providers, ultimately propelling growth in this dynamic market.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2025
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Regulatory Landscape
- Patent Analysis
Global Central Nervous System Biomarkers Market Size by Type & CAGR (2026-2033)
- Market Overview
- Safety Biomarkers
- Efficacy Biomarkers
- Validation Biomarkers
Global Central Nervous System Biomarkers Market Size by Application & CAGR (2026-2033)
- Market Overview
- Diagnostics
- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Stroke
- Drug Discovery & Development
- Preclinical Studies
- Clinical Trials
- Personalized Medicine
- Genomic Biomarkers
- Proteomic Biomarkers
- Metabolomic Biomarkers
Global Central Nervous System Biomarkers Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Diagnostic Laboratories
- Research Institutes
- Biopharmaceutical Companies
Global Central Nervous System Biomarkers Market Size & CAGR (2026-2033)
- North America (Type, Application, End-User)
- US
- Canada
- Europe (Type, Application, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Application, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Application, End-User)
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Application, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories International, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Axon Neuroscience SE (Slovakia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alector Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oryzon Genomics S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Banyan Biomarkers Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Avacta Group PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Geno Technology Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Anavex Life Sciences Corp. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alseres Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aposense Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
中樞神經系統生物標記市場按類型、適應症、技術、應用和最終用戶分類－2025-2032年全球預測
中樞神經系統生物標記市場 - 按生物標記類型、應用、最終用途 - 全球預測，2024 年 - 2032 年